Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.
Vermeeren A, Vets E, Vuurman EF, Van Oers AC, Jongen S, Laethem T, Heirman I, Bautmans A, Palcza J, Li X, Troyer MD, Wrishko R, McCrea J, Sun H. Vermeeren A, et al. Among authors: troyer md. Psychopharmacology (Berl). 2016 Sep;233(18):3341-51. doi: 10.1007/s00213-016-4375-x. Epub 2016 Jul 16. Psychopharmacology (Berl). 2016. PMID: 27424295 Free PMC article. Clinical Trial.
Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA. Schoedel KA, et al. Among authors: troyer md. J Clin Psychopharmacol. 2016 Aug;36(4):314-23. doi: 10.1097/JCP.0000000000000516. J Clin Psychopharmacol. 2016. PMID: 27253658 Clinical Trial.
Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.
Forman M, Palcza J, Tseng J, Stone JA, Walker B, Swearingen D, Troyer MD, Dockendorf MF. Forman M, et al. Among authors: troyer md. Clin Transl Sci. 2019 Sep;12(5):545-555. doi: 10.1111/cts.12645. Epub 2019 Jun 19. Clin Transl Sci. 2019. PMID: 31215755 Free PMC article. Clinical Trial.
Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
Chris Min K, Dockendorf MF, Palcza J, Tseng J, Ma L, Stone JA, Kleijn HJ, Hodsman P, Masuo K, Tanen M, Troyer MD, van Vugt M, Forman MS. Chris Min K, et al. Among authors: troyer md. Clin Pharmacol Ther. 2019 May;105(5):1234-1243. doi: 10.1002/cpt.1258. Epub 2019 Jan 18. Clin Pharmacol Ther. 2019. PMID: 30347431 Clinical Trial.
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF, Egan M, Ereshefsky L, Hodgson RA, Hyde LA, Jhee S, Kleijn HJ, Kuvelkar R, Li W, Mattson BA, Mei H, Palcza J, Scott JD, Tanen M, Troyer MD, Tseng JL, Stone JA, Parker EM, Forman MS. Kennedy ME, et al. Among authors: troyer md. Sci Transl Med. 2016 Nov 2;8(363):363ra150. doi: 10.1126/scitranslmed.aad9704. Sci Transl Med. 2016. PMID: 27807285
31 results